A Phase 2/3, Multicenter, Randomized, Double-Masked, 2-Year Trial of Pegaptanib Sodium for the Treatment of Diabetic Macular Edema

Sultan, Marla B.; Zhou, Duo; Loftus, Jane; Dombi, Theresa; Ice, Kathleen

doi:10.1016/j.ophtha.2011.02.045

Cited by 153 publications

(82 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On average, pegaptanib patients gained 5.2 letters of vision at year 1 compared to 1.2 letters for patients receiving sham. At the end of year 2, pegaptanib patients had gained on average 6.1 letters of vision compared to 1.3 letters for patients in the sham arm of the study (P , 0.01) (Sultan et al 2011).…”

Section: Role Of Angiogenic Factors In Diabetic Macular Edemamentioning

confidence: 89%

Antiangiogenic Therapy for Ischemic Retinopathies

Al-Latayfeh¹,

Silva²,

Sun³

et al. 2012

Cold Spring Harbor Perspectives in Medicine

View full text Add to dashboard Cite

Section: Role Of Angiogenic Factors In Diabetic Macular Edemamentioning

confidence: 89%

Antiangiogenic Therapy for Ischemic Retinopathies

Al-Latayfeh¹,

Silva²,

Sun³

et al. 2012

Cold Spring Harbor Perspectives in Medicine

View full text Add to dashboard Cite

“…In this study, intravitreal pegaptanib sodium 0.3 mg was well tolerated and demonstrated superior efficacy over the sham in the treatment of patients with DME. The proportion of patients with ≥10 letters (or 2 lines) of visual acuity improvement at week 54 was statistically significantly greater in the pegaptanib group versus those in the sham treatment arm (P = 0.0047; primary efficacy endpoint) (Sultan et al, 2011).…”

Section: Pegaptanibmentioning

confidence: 94%

Treatment of Diabetic Macular Edema – Latest Therapeutic Developments

Moon¹,

Kim²

2012

Diabetic Retinopathy

View full text Add to dashboard Cite

“…It was evaluated in a double-blind sham-controlled trial (ClinicalTrials.gov: NCT00605280), which found patients in the pegaptanib arm had a greater improvement in visual acuity and a reduced need for rescue focal/grid laser therapy at both 36 weeks and 2 years of follow-up [85]. It has not been evaluated in any other published trial comparing it head-tohead with other therapies.…”

Section: Anti-vegf Therapymentioning

confidence: 99%

Diabetic macular oedema: pathophysiology, management challenges and treatment resistance

Bahrami

Zhu

Hong³

et al. 2016

Diabetologia

View full text Add to dashboard Cite

Diabetic macular oedema (DMO) is the leading cause of vision loss in patients living with diabetes. DMO results from hyperglycaemia-induced activation of pathways that lead to oxidative stress and release of cytokines, impairing the inner and outer blood-retinal barriers. Improved understanding of the pathophysiological mechanisms leading to DMO have led to the development of effective therapies, including vitreoretinal surgery, laser photocoagulation, intravitreal anti-vascular endothelial growth factor drugs and corticosteroids. Advances in imaging, including fluorescein angiography and optical coherence tomography, have also enhanced diagnosis and management of the condition. Despite these advances, there remain patients who do not respond completely to therapy, reflecting the complex pathophysiology of DMO. These patients may be considered treatment-resistant. In this review, we summarise the pathophysiology of DMO, as well as the available treatments and their mechanism of action. Additionally, we focus on treatment-resistant disease and review the literature on potential options for managing this complication of diabetes.

show abstract

A Phase 2/3, Multicenter, Randomized, Double-Masked, 2-Year Trial of Pegaptanib Sodium for the Treatment of Diabetic Macular Edema

Cited by 153 publications

References 42 publications

Antiangiogenic Therapy for Ischemic Retinopathies

Antiangiogenic Therapy for Ischemic Retinopathies

Treatment of Diabetic Macular Edema – Latest Therapeutic Developments

Diabetic macular oedema: pathophysiology, management challenges and treatment resistance

Contact Info

Product

Resources

About